Literature DB >> 18599591

Cardiac ErbB-1/ErbB-2 mutant expression in young adult mice leads to cardiac dysfunction.

Viswanathan Rajagopalan1, Irving H Zucker, Jocelyn A Jones, Michaela Carlson, Ying J Ma.   

Abstract

Multiple factors lead to the development and maintenance of chronic heart failure. Blockade of ErbB-2 or ErbB-4 tyrosine kinase receptor signaling leads to dilated cardiomyopathy. ErbB-1 may protect the heart against stress-induced injury and its ligand; epidermal growth factor (EGF) increases myocardial contractility, whereas heparin-binding EGF is essential for normal cardiac function. However, the role of ErbB-1 in control of cardiac function is not clear. We hypothesized that ErbB-1 is essential for maintaining adult cardiac function. Using the ecdysone-inducible gene expression system, we expressed humanized cardiomyocyte-specific dominant-negative ErbB-1 mutant receptors (hErbB-1-mut) in young adult mice that block endogenous cardiac ErbB-1 signaling. Molecular, morphological, and physiological tests (under anesthesia) were performed. As a result, hErbB-1-mut was expressed selectively in cardiomyocytes leading to the blockade of endogenous ErbB-1 phosphorylation and ErbB-2 transphosphorylation. An increase in left ventricular mass, atrial natriuretic factor expression, and histological changes were indicative of cardiac hypertrophy. Cardiac dilation, numerous cardiac lesions, and the loss of the clear boundary between cardiac fibrils were noted histologically. Early and long-term hErbB-1-mut induction led to a significant decrease in fractional shortening and to significant increases in left ventricular end-systolic diameter and volume. The treatment of adenylyl cyclase activator (forskolin analog) normalized the depressed cardiac function. Resting cardiac function returned to normal after reversing mutant expression. A 4-day survival rate of transverse-aortic constricted hErbB-1-mut mice was only 20% compared with 100% in controls. In conclusion, these observations indicate that the blockade of cardiac ErbB-1 signaling leads to the blockade of ErbB-2 signaling and that together they result in cardiac dysfunction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18599591     DOI: 10.1152/ajpheart.91436.2007

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  11 in total

Review 1.  Role of thyroid hormones in ventricular remodeling.

Authors:  Viswanathan Rajagopalan; A Martin Gerdes
Journal:  Curr Heart Fail Rep       Date:  2015-04

2.  A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform.

Authors:  Susann Albert; Claudia Arndt; Anja Feldmann; Ralf Bergmann; Dominik Bachmann; Stefanie Koristka; Florian Ludwig; Pauline Ziller-Walter; Alexandra Kegler; Sebastian Gärtner; Marc Schmitz; Armin Ehninger; Marc Cartellieri; Gerhard Ehninger; Hans-Jürgen Pietzsch; Jens Pietzsch; Jörg Steinbach; Michael Bachmann
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

3.  Epidermal growth factor protects the heart against low-flow ischemia-induced injury.

Authors:  J Lorita; M Soley; I Ramírez
Journal:  J Physiol Biochem       Date:  2010-04-27       Impact factor: 4.158

Review 4.  Cardiovascular Risks with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and Monoclonal Antibody Therapy.

Authors:  Kalyan R Chitturi; Ethan A Burns; Ibrahim N Muhsen; Kartik Anand; Barry H Trachtenberg
Journal:  Curr Oncol Rep       Date:  2022-02-22       Impact factor: 5.075

5.  Reduced EGFR causes abnormal valvular differentiation leading to calcific aortic stenosis and left ventricular hypertrophy in C57BL/6J but not 129S1/SvImJ mice.

Authors:  Cordelia J Barrick; Reade B Roberts; Mauricio Rojas; Nalini M Rajamannan; Carolyn B Suitt; Kevin D O'Brien; Susan S Smyth; David W Threadgill
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-05-15       Impact factor: 4.733

6.  Transcription-independent Induction of ERBB1 through Hypoxia-inducible Factor 2A Provides Cardioprotection during Ischemia and Reperfusion.

Authors:  Jae W Lee; Michael Koeppen; Seong-Wook Seo; Jessica L Bowser; Xiaoyi Yuan; Jiwen Li; Maria Sibilia; Amrut V Ambardekar; Xu Zhang; Tobias Eckle; Seung-Hee Yoo; Holger K Eltzschig
Journal:  Anesthesiology       Date:  2020-04       Impact factor: 7.892

7.  Epidermal growth factor receptor-dependent maintenance of cardiac contractility.

Authors:  Shuchi Guo; Ama Dedo Okyere; Erin McEachern; Joshua L Strong; Rhonda L Carter; Viren C Patwa; Toby P Thomas; Melissa Landy; Jianliang Song; Ana Maria Lucchese; Thomas G Martin; Erhe Gao; Sudarsan Rajan; Jonathan A Kirk; Walter J Koch; Joseph Y Cheung; Douglas G Tilley
Journal:  Cardiovasc Res       Date:  2022-03-25       Impact factor: 13.081

8.  Integrated Analysis of circRNA-miRNA-mRNA ceRNA Network in Cardiac Hypertrophy.

Authors:  Yang-Hao Chen; Ling-Feng Zhong; Xia Hong; Qian-Li Zhu; Song-Jie Wang; Ji-Bo Han; Wei-Jian Huang; Bo-Zhi Ye
Journal:  Front Genet       Date:  2022-02-08       Impact factor: 4.599

9.  Gene expression in uterine leiomyoma from tumors likely to be growing (from black women over 35) and tumors likely to be non-growing (from white women over 35).

Authors:  Barbara J Davis; John I Risinger; Gadisetti V R Chandramouli; Pierre R Bushel; Donna Day Baird; Shyamal D Peddada
Journal:  PLoS One       Date:  2013-06-13       Impact factor: 3.240

Review 10.  The epidermal growth factor receptor and its ligands in cardiovascular disease.

Authors:  Nader Makki; Kristina W Thiel; Francis J Miller
Journal:  Int J Mol Sci       Date:  2013-10-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.